Kooij Louise Frederika's Form 4 filing
NewAmsterdam Pharma Co N.V.NAMS · filed Sep 5, 2025
- Accession no.
- 0000950170-25-113276
- Filed
- Sep 5, 2025
- Trade date
- Sep 3, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $453.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kooij Louise FrederikaCIK 0002004379 | Officer (Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2025 | Ordinary Shares | SSaleDisposed | −18,073 | $25.09F1 | −$453,451.57 | 15,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price provided by the broker; additional information, including the price range, if any, is unavailable at the time of filing.
Referenced by the price of 1 transaction in Table I.